In MI following are used except
Ref Harrison 19 th ed pg 1605 The principal goal of fibrinolysis is prompt restoration of full coronary aerial patency. The fibrinolytic agents tissue plasminogen activator (tPA), streptokinase, tenecteplase (TNK), and reteplase (rPA) have been approved by the U.S. Food and Drug Administration for intravenous use in patients with STEMI. These drugs all act by promoting the conversion of plasminogen to plas- min, which subsequently lyses fibrin thrombi.
Fibrinolytics
Plasminogen activator inhibitor
Antithrombin
Platelet inhibitor
C.V.S